Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIACADADMAAGIOALMSALMUALTSAPGEAUPHAVAVBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTRIGCTGOOGGPCRHALOHIMSHOODHWMIRENIVVDKALAKALVLENZLEVILITELRMRLULULUNRMDGLMESOMOHMTCHMUMVSTNBISNKENRIXNVAXOKUROLMAONCOSCRPHATPLRXPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHAUNHVEONVORWVEXFORZLAB
Rigel Pharmaceuticals (RIGL) presents a compelling investment opportunity as it transitions from R&D to a profitable commercial biotech. Its diversified portfolio—TAVALISSE (ITP), REZLIDHIA (AML), and GAVRETO (NSCLC)—drove 2025 revenue guidance upward to $270-280M and sustained profitability. The pipeline asset R289 (Phase 1b IRAK1/4 inhibitor for LR-MDS) represents significant upside as a "free call option," with catalysts including 2025 data readouts. A Sum-of-the-Parts valuation yields a $38 price target (74% upside), supported by commercial execution, patent protection through 2032-2041, and strong cash flow to self-fund growth. Risks include clinical setbacks and competition. Recommendation: BUY.

Rigel Pharmaceuticals (RIGL): An Undervalued Commercial Biotech at a Profitability Inflection Point

2025-08-07Change from report: -4.1%1M: +34.3%3M: +15.6%

Rigel Pharmaceuticals (RIGL) presents a compelling investment opportunity as it transitions from R&D to a profitable commercial biotech. Its diversified portfolio—TAVALISSE (ITP), REZLIDHIA (AML), and GAVRETO (NSCLC)—drove 2025 revenue guidance upward to $270-280M and sustained profitability. The pipeline asset R289 (Phase 1b IRAK1/4 inhibitor for LR-MDS) represents significant upside as a "free call option," with catalysts including 2025 data readouts. A Sum-of-the-Parts valuation yields a $38 price target (74% upside), supported by commercial execution, patent protection through 2032-2041, and strong cash flow to self-fund growth. Risks include clinical setbacks and competition. Recommendation: BUY.